temperature excursion with no reported adverse event; Initial information received on 04-Mar-2022 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves Adult and unknown gender patient who reported  temperature excursion with no reported adverse event while receiving vaccines INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT] and INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [FLUBLOK QIV] and while treated with RASBURICASE [ELITEK], INSULIN GLULISINE [APIDRA SOLOSTAR], INSULIN GLULISINE [APIDRA], INSULIN GLARGINE, LIXISENATIDE [SOLIQUA], INSULIN LISPRO [ADMELOG], TUBERCULIN TEST [TUBERSOL], INSULIN GLARGINE [LANTUS SOLOSTAR], INSULIN GLARGINE [LANTUS VIAL] and INSULIN LISPRO [ADMELOG SOLOSTAR]. The patient's past medical history, medical treatment(s), vaccination(s), concomitant(s) and family history were not provided.    On an unknown date ELITEK (RASBURICASE) 1.5 mg and dosage was changed to 7.5 mg (with an unknown batch number, formulation, strength, route, frequency and expiry date), APIDRA SOLOSTAR (INSULIN GLULISINE) dosage unknown (with an unknown batch number, formulation, strength, route, frequency and expiry date), APIDRA (INSULIN GLULISINE) dosage unknown (with an unknown batch number, formulation, strength, route, frequency and expiry date), SOLIQUA (INSULIN GLARGINE, LIXISENATIDE) dosage unknown (with an unknown batch number, formulation, strength, route, frequency and expiry date), ADMELOG (INSULIN LISPRO) dosage unknown (with an unknown batch number, formulation, strength, route, frequency and expiry date), TUBERSOL (TUBERCULIN TEST) dosage unknown (with an unknown batch number, formulation, strength, route, frequency and expiry date), LANTUS SOLOSTAR (INSULIN GLARGINE) dosage unknown (with an unknown batch number, formulation, strength, route, frequency and expiry date), LANTUS VIAL (INSULIN GLARGINE) dosage unknown (with an unknown batch number, formulation, strength, route, frequency and expiry date) and ADMELOG SOLOSTAR (INSULIN LISPRO) dosage unknown (with an unknown batch number, formulation, strength, route, frequency and expiry date) for unknown indication. On an unknown date, the patient received a dose of suspect INFLUENZA QUADRIVALENT RECOMBINANT VACCINE lot number not reported. On an unknown date, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B VACCINE lot number not reported.  On an unknown date the patient developed a non-serious event "temperature excursion with no reported adverse event" (product temperature excursion issue) (unknown latency) following the first dose intake of RASBURICASE, (unknown latency) following the first dose intake of INSULIN GLULISINE, (unknown latency) following the first dose intake of INSULIN GLULISINE, (unknown latency) following the first dose intake of INSULIN GLARGINE, LIXISENATIDE, (unknown latency) following the first dose intake of INSULIN LISPRO, (unknown latency) following the first dose intake of TUBERCULIN TEST, (unknown latency) following the first dose intake of INSULIN GLARGINE, (unknown latency) following the first dose intake of INSULIN GLARGINE and (unknown latency) following the first dose intake of INSULIN LISPRO.On an unknown date the patient developed a non-serious temperature excursion with no reported adverse event (product temperature excursion issue) (unknown latency) following the administration of INFLUENZA QUADRIVALENT RECOMBINANT VACCINE and (unknown latency) following the administration of INFLUENZA QUADRIVAL A-B VACCINE.  It was reported "She states that she is calling for extended stability data for a temperature excursion. She states that the refrigerator door was left open overnight for 13 hours. She states that everything is unopened."   Action taken with RASBURICASE (ELITEK), INSULIN GLULISINE (APIDRA SOLOSTAR), INSULIN GLULISINE (APIDRA), INSULIN GLARGINE, LIXISENATIDE (SOLIQUA), INSULIN LISPRO (ADMELOG), INSULIN LISPRO (ADMELOG SOLOSTAR), TUBERCULIN TEST (TUBERSOL), INSULIN GLARGINE (LANTUS SOLOSTAR), INSULIN GLARGINE (LANTUS VIAL), QUADRIVALENT RECOMBINANT INFLUENZA VACCINE (FLUBLOK QIV) and QUADRIVALENT INFLUENZA VACCINE (FLUZONE QUADRIVALENT) was not applicable.   At time of reporting, the outcome was Unknown for the event temperature excursion with no reported adverse event.